AstraZeneca Gets Fast Imfinzi Review For SCLC
Will Compete With Roche’s Tecentriq
The drug major has won a priority review for Imfinzi in small cell lung cancer from the FDA. If approved, the new indication could add $1bn to sales of the checkpoint inhibitor
